This thesis consisted of experiments designed to explore the construct of attention and investigate the disruptive effects of psychotomimetics, with a specific focus on NMDA antagonists. Phencyclidine (PCP) was administered through a variety of treatment regimens in order to to determine the ability of inducing cognitive-specific disruptions in attentional functioning. The hypothesis that sub-chronic exposure to PCP would result in persistent attentional impairment was tested, using the 5-choice serial reaction time task (5-CSRTT). The 5-CSRTT assesses not only visuospatial attention, but also components of impulsivity, compulsivity, speed of processing and motivation. It was determined that an additional task-related intervention that increased the attentional load was required to elucidate attentional impairment following sub-chronic PCP treatment. The ability of rats to perform the modified version of the 5-CSRTT, known as the 5-choice continuous performance test (5C-CPT), was investigated. The 5C-CPT was implemented to provide a task that may have greater analogy to the human CPT, than the original 5-CSRTT. The consequence of dopaminergic D1 system activation was investigated. It was revealed that D1 partial agonism improved attentional performance in a baseline-dependent manner. Following successful acquisition of the task, it was shown that repeated PCP treatment induced cognitive disruption that was cognitive-specific, and not confounded by generalised response disruption. Furthermore, a partial attenuation of the PCP-induced performance disruption was achieved following administration of the D1 partial agonist, SKF 38393. Moreover, sub-chronic PCP treatment was shown to impair 5C-CPT performance in the drug-free state. However, an additional challenge that further increased the attentional load was needed to elucidate a performance deficit. This highlighted that sustained attention/vigilance is sensitive to persistent impairment following sub-chronic PCP administration in a manner consistent with deficits observed in schizophrenia patients. This prompted the investigation that tested the hypothesis that sub-chronic PCP treatment could induce enduring structural deficits in regions associated with attentional performance. Magnetic resonance imaging (MRI) was conducted, in conjunction with 5-CSRTT and pre-pulse inhibition (PPI). It was revealed that sub-chronic PCP treatment resulted in morphological brain abnormalities in brain regions associated with 5-CSRTT performance. This was coupled with deficits in sustained attentional performance following an increase in attentional load, yet PPI was unaffected. Taken together, these findings suggested sub-chronic PCP treatment impairs attentional functionality, an effect that dissociates between effortful and passive attentional processes.

This thesis consisted of experiments designed to explore the construct of attention and investigate the disruptive effects of psychotomimetics, with a specific focus on NMDA antagonists. Phencyclidine (PCP) was administered through a variety of treatment regimens in order to to determine the ability of inducing cognitive-specific disruptions in attentional functioning. The hypothesis that sub-chronic exposure to PCP would result in persistent attentional impairment was tested, using the 5-choice serial reaction time task (5-CSRTT). The 5-CSRTT assesses not only visuospatial attention, but also components of impulsivity, compulsivity, speed of processing and motivation. It was determined that an additional task-related intervention that increased the attentional load was required to elucidate attentional impairment following sub-chronic PCP treatment. The ability of rats to perform the modified version of the 5-CSRTT, known as the 5-choice continuous performance test (5C-CPT), was investigated. The 5C-CPT was implemented to provide a task that may have greater analogy to the human CPT, than the original 5-CSRTT. The consequence of dopaminergic D1 system activation was investigated. It was revealed that D1 partial agonism improved attentional performance in a baseline-dependent manner. Following successful acquisition of the task, it was shown that repeated PCP treatment induced cognitive disruption that was cognitive-specific, and not confounded by generalised response disruption. Furthermore, a partial attenuation of the PCP-induced performance disruption was achieved following administration of the D1 partial agonist, SKF 38393. Moreover, sub-chronic PCP treatment was shown to impair 5C-CPT performance in the drug-free state. However, an additional challenge that further increased the attentional load was needed to elucidate a performance deficit. This highlighted that sustained attention/vigilance is sensitive to persistent impairment following sub-chronic PCP administration in a manner consistent with deficits observed in schizophrenia patients. This prompted the investigation that tested the hypothesis that sub-chronic PCP treatment could induce enduring structural deficits in regions associated with attentional performance. Magnetic resonance imaging (MRI) was conducted, in conjunction with 5-CSRTT and pre-pulse inhibition (PPI). It was revealed that sub-chronic PCP treatment resulted in morphological brain abnormalities in brain regions associated with 5-CSRTT performance. This was coupled with deficits in sustained attentional performance following an increase in attentional load, yet PPI was unaffected. Taken together, these findings suggested sub-chronic PCP treatment impairs attentional functionality, an effect that dissociates between effortful and passive attentional processes.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22745号 / 医博第4663号 / 新制||医||1046(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 林 康紀, 教授 伊佐 正, 教授 村井 俊哉 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Rationale. Adolescence may be a period of susceptibility to the effects of drugs of abuse. This vulnerability may result from a convergence of psychological processes that contribute to drug addiction including impulsive action and incentive motivation during adolescence. Objectives. I examined age differences in incentive motivation, as measured by responding for a conditioned reinforcer (CR) previously paired with natural or drug rewards, and age and sex differences in impulsive action, as measured by responding on a differential reinforcement of low rates of responding (DRL) schedule or premature responding on the 2-Choice Serial Reaction Time Test (2-CSRTT), in Sprague-Dawley rats. The effects of drugs that affect these behaviours in adulthood and that act on neurochemical systems still developing during adolescence were also examined. Methods. In a first set of experiments (Chapter 3), I compared male adolescents and adults on responding for a CR previously paired with sucrose and the effect of amphetamine on this behaviour. In a second set of experiments (Chapter 4), I examined age differences in responding for a CR previously paired with passive or self-administered intravenous (IV) nicotine infusions. Subsequently, I investigated age and sex differences in responding on a DRL schedule in response to amphetamine (Chapter 5) and 2-CSRTT performance in response to amphetamine, nicotine and Ro 63-1908 (a glutamate N-Methyl-D-aspartic acid [NMDA] receptor subunit antagonist; Chapter 6). Results. Compared to adults, adolescents responded more for a CR previously paired with sucrose or passive, but not self-administered, IV nicotine infusions. Amphetamine only enhanced responding for a CR previously paired with sucrose. Adolescents responded more than adults on a DRL schedule, while adolescents made the most premature responses in the 2-CSRTT. No consistent sex differences were observed during the acquisition of either behaviour. Amphetamine increased premature responding most in adolescent males and adult females in the 2-CSRTT but not in responding on the DRL schedule. No consistent age or sex differences were observed for Ro 63-1908 or nicotine. Conclusions. Adolescents show enhanced impulsivity and incentive motivation than adults depending on the behavioural measure. Dopamine may contribute to age and sex differences in these behaviours.

No description available.